Aarti Drugs Q1 FY26 results (Apr–Jun 2025) and concall

Aarti Drugs reported a solid Q1 FY26 with total revenues growing 6% YoY to INR591 crores and EBITDA increasing 12% YoY to INR74 crores, driven by improved gross margins of 36.8%. The company's greenfield project at Sayakha has commenced trial production, expected to contribute from Q3 FY26, and the Tarapur salicylic acid plant is ramping up operations despite initial challenges and price dumping from China. USFDA and UK MHRA approvals for formulation facilities position the company for growth in regulated markets, with a target of 15% CAGR volume growth for FY26 and FY27.